SYNERGY VACCINES, INC ENABLING TOMORROW'S VACCINES TODAY    SynerVax™ vaccine adjuvant is based on a proprietary methodology for complexing antigens with alpha-2-macroglobulin (alpha2M). The resulting vaccines are much more effectively processed by antigen presenting cells, resulting in enhanced immune responses. Synergy’s enabling technology platform allows for the efficient incorporation of antigens into alpha2M. This process is so gentle that it maintains antigen integrity, adds stability, prolongs shelf life and avoids the "cold chain" requirement for shipping and storage. SynerVax™ vaccine adjuvant lowers vaccine dosage by an order of magnitude or more with corresponding reductions in vaccine costs and side effects. SynerVax™ vaccine adjuvant shields antigens from proteases or existing antibodies until they are taken up, in a receptor-specific manner, by the appropriate immune cells. SynerVax™ vaccine adjuvant is a safe, natural, and extremely effective way to elicit extremely strong antibody and CTL responses to subunit antigens. Hepatitis - B, C AIDS Cancer - melanoma - prostate Alzheimer's Disease Malaria Biological Agents - anthrax - plague - toxins Veterinary - companion animal vaccines - livestock vaccines SynerVax™ Adjuvant - entirely natural - eliminates adjuvant-associated side effects SynerVax™ Adjuvant Provides Existing Vaccines with - increased immunogenicity - fewer doses - proprietary status - greater cost savings SynerVax™ Adjuvant Protects Antigens from - degradation by proteases - clearance by existing antibodies SynerVax™ Adjuvant Enables: - most subunit vaccines - human or veterinary vaccines - therapeutic vaccines - preventative vaccines